Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

Study Status

Open to Enrollment

Study Description

This clinical trial is for men and women with chronic hepatitis C, genotype 1b who have either

  • Never received any prior treatment for hepatitis C, or
  • Relapsed after an initially successful treatment with alfa + ribavirin

Peginterferon lambda-1a (also called Lambda) is an experimental drug being studied for the treatment of hepatitis B and C. Lambda is an injectable medication and is in the same class of interferon drugs as peginterferon alfa-2a (also called alfa). Because of the differences in the way Lambda and alfa bind to cells, there may be fewer side effects associated with Lambda treatment.

Daclatasvir is an experimental drug and not FDA-approved. Daclatasvir is part of a new class of antiviral drugs being studied in combination with interferon + RBV in the treatment of hepatitis C.  These drugs have been shown to have specific activity against hepatitis C and little significant side effects.  Combining antiviral drugs with Lambda+RBV or alfa+RBV could make treatment for hepatitis C more effective. 

Alfa and telaprevir are FDA-approved for treating hepatitis C.

The purpose of this study is to determine if treatment with Lambda, given in combination with ribavirin and daclatasvir for 24 weeks, is safe and effective as compared to the standard treatment with alfa + ribavirin + telaprevir.

Study participants will be randomly assigned to one of two treatment groups:

  • Group 1:
    • Lambda self-injected subcutaneously (under the skin) once a week for up to 24 weeks
    • Ribavirin by mouth twice a day for up to 24 weeks
    • Daclatasvir by mouth once  a day for up to 24 weeks
  • Group 2:
    • Alfa self-injected subcutaneously once a week for up to 48 weeks
    • Ribavirin by mouth twice a day for up to 48 weeks
    • Telaprevir by mouth 3 times a day for up to 12 weeks

Study participation is expected to be 48 to 72 weeks (including study treatment and post-treatment follow-up), depending on which treatment group a participant is assigned to and response to treatment.

Disease Status and/or Stage

Chronic Hepatitis C, Untreated or Previously Treated


Bristol-Myers Squibb

Key Eligibility

  • Men and women age 18 and older
  • Chronic Hepatitis C Genotype 1b, and either:
    • No previous treatment for hepatitis C, or
    • Relapsed after an initially successful treatment with alfa + ribavirin
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Sonal Kumar, MD


  • Hepatitis Research Team
  • 646-962-HEPC (4372)

Protocol ID

BMS AI452021

Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page